Get the Stockscreener App
5.91
6.68%
0.37
Pre-market:
5.93
0.02
+0.34%
Kalaris Therapeutics Inc stock is traded at $5.91, with a volume of 202.53K.
It is up +6.68% in the last 24 hours and up +25.48% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$5.54
Open:
$5.54
24h Volume:
202.53K
Relative Volume:
0.59
Market Cap:
$110.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.23%
1M Performance:
+25.48%
6M Performance:
+91.26%
1Y Performance:
+0.00%
1-Day Range:
$5.33
$6.00
1-Week Range:
$5.10
$6.54
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.91 | 103.61M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Is Kalaris Therapeutics Inc. stock a good choice for value investorsPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $11.50 Consensus Target Price from Brokerages - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Yahoo Finance
What analysts say about Kalaris Therapeutics Inc stockCandlestick Pattern Analysis & Rapid Capital Growth - earlytimes.in
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - The Globe and Mail
Kalaris (Nasdaq: KLRS) to present at Noble Capital 21st Emerging Growth Conference - Stock Titan
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kalaris Therapeutics, Inc. (KLRS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
What risks investors should watch in Kalaris Therapeutics Inc. stockJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Equities Analysts Offer Predictions for KLRS Q4 Earnings - Defense World
Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans - Sahm
What’s next for Kalaris Therapeutics Inc. stock priceTrade Exit Summary & Trade Opportunity Analysis - newser.com
Will Kalaris Therapeutics Inc. stock benefit from commodity pricesLong Setup & Daily Volume Surge Trade Alerts - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - newser.com
Can Kalaris Therapeutics Inc. stock deliver surprise earnings beat - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsMarket Growth Summary & Stepwise Trade Execution Plans - newser.com
Kalaris stock rating reiterated at Strong Buy by Raymond James - Investing.com Canada
Kalaris Therapeutics Reports Q3 2025 Financial Progress - MSN
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsWeekly Investment Report & Verified Momentum Watchlists - newser.com
Kalaris Therapeutics (KLRS) Price Target Increased by 10.87% to 17.34 - Nasdaq
Analyzing Kalaris Therapeutics Inc. with risk reward ratio charts2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
Applying sector rotation models to Kalaris Therapeutics Inc.Oil Prices & Technical Confirmation Trade Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysMarket Performance Summary & Consistent Profit Trading Strategies - newser.com
Does Kalaris Therapeutics Inc. qualify in momentum factor screeningMarket Rally & AI Driven Price Predictions - newser.com
William Blair Has Negative Estimate for KLRS FY2025 Earnings - Defense World
Is Kalaris Therapeutics Inc. stock positioned for digital transformationLong Setup & Expert Verified Movement Alerts - newser.com
How resilient is Kalaris Therapeutics Inc. stock in market downturnsWeekly Profit Summary & Daily Volume Surge Trade Alerts - newser.com
Will Kalaris Therapeutics Inc. outperform the marketGap Down & Fast Moving Stock Watchlists - newser.com
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):